Phase 1 Study to Assess the Safety and Pharmacokinetics of Elexacaftor/Tezacaftor/Ivacaftor in Subjects Without Cystic Fibrosis With Moderate Hepatic Impairment

to related objects

Location: Deutsche Nationalbibliothek Frankfurt am Main

ISSN: 2107-0180

Extent: Online-Ressource

Language: Englisch

Notes: online resource.

Bibliographic citation: Phase 1 Study to Assess the Safety and Pharmacokinetics of Elexacaftor/Tezacaftor/Ivacaftor in Subjects Without Cystic Fibrosis With Moderate Hepatic Impairment ; volume:47 ; number:6 ; day:29 ; month:8 ; year:2022 ; pages:817-825 ; date:11.2022
European journal of drug metabolism and pharmacokinetics ; 47, Heft 6 (29.8.2022), 817-825, 11.2022

Creator: Viswanathan, Lakshmi
Bachman, Eric
Tian, Simon
Ahluwalia, Neil
Zhang, Yaohua
Bernstein, Harold S.
Panorchan, Paul

Contributor: SpringerLink (Online service)

DOI: 10.1007/s13318-022-00791-8

URN: urn:nbn:de:101:1-2023011821381523626456

Rights: Open Access; Der Zugriff auf das Objekt ist unbeschränkt möglich.

Last update: 15.08.2025, 7:39 AM CEST

Data provider

This object is provided by:
Deutsche Nationalbibliothek. If you have any questions about the object, please contact the data provider.

Show original at data provider

Associated

Viswanathan, Lakshmi
Bachman, Eric
Tian, Simon
Ahluwalia, Neil
Zhang, Yaohua
Bernstein, Harold S.
Panorchan, Paul
SpringerLink (Online service)

Other Objects (12)

Influence of mild and moderate hepatic impairment on axitinib pharmacokinetics

Pharmacokinetics of afatinib in subjects with mild or moderate hepatic impairment

Pharmacokinetics and safety of niraparib in patients with moderate hepatic impairment

Pharmacokinetics and Tolerability of Zibotentan in Patients with Concurrent Moderate Renal and Moderate Hepatic Impairment

Apixaban Pharmacokinetics and Pharmacodynamics in Subjects with Mild or Moderate Hepatic Impairment

Long-Term Ivacaftor in People Aged 6 Years and Older with Cystic Fibrosis with Ivacaftor-Responsive Mutations

Lumacaftor/ivacaftor in cystic fibrosis: effects on glucose metabolism and insulin secretion

Predicting lung function decline in cystic fibrosis: the impact of initiating ivacaftor therapy

Pharmacokinetics and Safety of Single-Dose Esaxerenone in Japanese Subjects with Mild to Moderate Hepatic Impairment

Pharmacokinetics of Omadacycline in Adults with Cystic Fibrosis

Lumacaftor/ Ivacaftor improves exercise tolerance in patients with Cystic Fibrosis and severe airflow obstruction

Real-World Outcomes Among Patients with Cystic Fibrosis Treated with Ivacaftor: 2012–2016 Experience

Influence of mild and moderate hepatic impairment on axitinib pharmacokinetics

Pharmacokinetics of afatinib in subjects with mild or moderate hepatic impairment

Pharmacokinetics and safety of niraparib in patients with moderate hepatic impairment

Pharmacokinetics and Tolerability of Zibotentan in Patients with Concurrent Moderate Renal and Moderate Hepatic Impairment

Apixaban Pharmacokinetics and Pharmacodynamics in Subjects with Mild or Moderate Hepatic Impairment

Long-Term Ivacaftor in People Aged 6 Years and Older with Cystic Fibrosis with Ivacaftor-Responsive Mutations

Lumacaftor/ivacaftor in cystic fibrosis: effects on glucose metabolism and insulin secretion

Predicting lung function decline in cystic fibrosis: the impact of initiating ivacaftor therapy

Pharmacokinetics and Safety of Single-Dose Esaxerenone in Japanese Subjects with Mild to Moderate Hepatic Impairment

Pharmacokinetics of Omadacycline in Adults with Cystic Fibrosis

Lumacaftor/ Ivacaftor improves exercise tolerance in patients with Cystic Fibrosis and severe airflow obstruction

Real-World Outcomes Among Patients with Cystic Fibrosis Treated with Ivacaftor: 2012–2016 Experience

Influence of mild and moderate hepatic impairment on axitinib pharmacokinetics

Pharmacokinetics of afatinib in subjects with mild or moderate hepatic impairment

Pharmacokinetics and safety of niraparib in patients with moderate hepatic impairment

Pharmacokinetics and Tolerability of Zibotentan in Patients with Concurrent Moderate Renal and Moderate Hepatic Impairment

Apixaban Pharmacokinetics and Pharmacodynamics in Subjects with Mild or Moderate Hepatic Impairment

Long-Term Ivacaftor in People Aged 6 Years and Older with Cystic Fibrosis with Ivacaftor-Responsive Mutations

Lumacaftor/ivacaftor in cystic fibrosis: effects on glucose metabolism and insulin secretion

Predicting lung function decline in cystic fibrosis: the impact of initiating ivacaftor therapy

Pharmacokinetics and Safety of Single-Dose Esaxerenone in Japanese Subjects with Mild to Moderate Hepatic Impairment

Pharmacokinetics of Omadacycline in Adults with Cystic Fibrosis

Lumacaftor/ Ivacaftor improves exercise tolerance in patients with Cystic Fibrosis and severe airflow obstruction

Real-World Outcomes Among Patients with Cystic Fibrosis Treated with Ivacaftor: 2012–2016 Experience

Cultural heritage institutions wishing to register will find more information here.

Fields marked * need to be filled in.

Username*

Please enter your username

Email*

Please enter your email address

Please do not fill this field

First name

Last name

Password*

Please enter your password

Confirm password*

Please enter the same password

I have read the terms of use and the privacy policy for the collection of personal data and accept them. *

This field is required.

I would like to subscribe to the newsletter of the Deutsche Digitale Bibliothek. See newsletter subscription info.

Account created

Your "My DDB" account has been successfully created. Before you can log in to your account, you must click the confirmation link in the message we just sent to the email address you provided.

Phase 1 Study to Assess the Safety and Pharmacokinetics of Elexacaftor/Tezacaftor/Ivacaftor in Subjects Without Cystic Fibrosis With Moderate Hepatic Impairment

Object Details

References and Relationships

Contributors, Places and Time

Further information

Data provider

Associated

Other Objects (12)

Influence of mild and moderate hepatic impairment on axitinib pharmacokinetics

Pharmacokinetics of afatinib in subjects with mild or moderate hepatic impairment

Pharmacokinetics and safety of niraparib in patients with moderate hepatic impairment

Pharmacokinetics and Tolerability of Zibotentan in Patients with Concurrent Moderate Renal and Moderate Hepatic Impairment

Apixaban Pharmacokinetics and Pharmacodynamics in Subjects with Mild or Moderate Hepatic Impairment

Long-Term Ivacaftor in People Aged 6 Years and Older with Cystic Fibrosis with Ivacaftor-Responsive Mutations

Lumacaftor/ivacaftor in cystic fibrosis: effects on glucose metabolism and insulin secretion

Predicting lung function decline in cystic fibrosis: the impact of initiating ivacaftor therapy

Pharmacokinetics and Safety of Single-Dose Esaxerenone in Japanese Subjects with Mild to Moderate Hepatic Impairment

Pharmacokinetics of Omadacycline in Adults with Cystic Fibrosis

Lumacaftor/ Ivacaftor improves exercise tolerance in patients with Cystic Fibrosis and severe airflow obstruction

Real-World Outcomes Among Patients with Cystic Fibrosis Treated with Ivacaftor: 2012–2016 Experience

Influence of mild and moderate hepatic impairment on axitinib pharmacokinetics

Pharmacokinetics of afatinib in subjects with mild or moderate hepatic impairment

Pharmacokinetics and safety of niraparib in patients with moderate hepatic impairment

Pharmacokinetics and Tolerability of Zibotentan in Patients with Concurrent Moderate Renal and Moderate Hepatic Impairment

Apixaban Pharmacokinetics and Pharmacodynamics in Subjects with Mild or Moderate Hepatic Impairment

Long-Term Ivacaftor in People Aged 6 Years and Older with Cystic Fibrosis with Ivacaftor-Responsive Mutations

Lumacaftor/ivacaftor in cystic fibrosis: effects on glucose metabolism and insulin secretion

Predicting lung function decline in cystic fibrosis: the impact of initiating ivacaftor therapy

Pharmacokinetics and Safety of Single-Dose Esaxerenone in Japanese Subjects with Mild to Moderate Hepatic Impairment

Pharmacokinetics of Omadacycline in Adults with Cystic Fibrosis

Lumacaftor/ Ivacaftor improves exercise tolerance in patients with Cystic Fibrosis and severe airflow obstruction

Real-World Outcomes Among Patients with Cystic Fibrosis Treated with Ivacaftor: 2012–2016 Experience

Influence of mild and moderate hepatic impairment on axitinib pharmacokinetics

Pharmacokinetics of afatinib in subjects with mild or moderate hepatic impairment

Pharmacokinetics and safety of niraparib in patients with moderate hepatic impairment

Pharmacokinetics and Tolerability of Zibotentan in Patients with Concurrent Moderate Renal and Moderate Hepatic Impairment

Apixaban Pharmacokinetics and Pharmacodynamics in Subjects with Mild or Moderate Hepatic Impairment

Long-Term Ivacaftor in People Aged 6 Years and Older with Cystic Fibrosis with Ivacaftor-Responsive Mutations

Lumacaftor/ivacaftor in cystic fibrosis: effects on glucose metabolism and insulin secretion

Predicting lung function decline in cystic fibrosis: the impact of initiating ivacaftor therapy

Pharmacokinetics and Safety of Single-Dose Esaxerenone in Japanese Subjects with Mild to Moderate Hepatic Impairment

Pharmacokinetics of Omadacycline in Adults with Cystic Fibrosis

Lumacaftor/ Ivacaftor improves exercise tolerance in patients with Cystic Fibrosis and severe airflow obstruction

Real-World Outcomes Among Patients with Cystic Fibrosis Treated with Ivacaftor: 2012–2016 Experience

Related objects

Reset password